Focus:

Medical Devices, Therapeutics, Diagnostics and Auxiliary Technologies

Type:

Development and expansion capital funding clinical trials and commercialisation.

Geography:

Australia / New Zealand

Committed Capital:

A$42 million (Closed June 2010).

Investment Strategy:

Active investment in the Australasian bioscience ‘mid stage’ companies, targeting outstanding technologies near or in clinical trial that offer international commercial opportunity and superior investment return.